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surement withmore than one endpoint is the generation of a cardinal index/score.
Without the prioritization and weighting of multiple endpoints a deduction of
recommendationsmight be questionable.METHODS: A pilot study was conducted
to elicit patients’ preferences about antiviral therapy of chronic hepatitis C. For the
Discrete-Choice-Experiment (DCE), 7 attributes were selected with 3 Levels each.
Therefore an orthogonal, balanced and efficient design was used and results were
analysed with random effects logit models. RESULTS: Patients and experts priori-
tized the respective endpoints in almost the same order, but weighted them differ-
ently. Sustained-Virological-Response received the highest weight followed by fre-
quency of application (patients) or duration of therapy (experts).CONCLUSIONS:Aim
was to demonstrate how DCEs can be used to empirically determine which PREs
should be included in the efficiency frontier analysis. Further it is demonstrated
how such methods can be used to prioritize across such multiple efficiency fron-
tiers. The survey demonstrated how DCEs could be used to empirically determine
which PREs are important in antiviral treatment of chronic hepatitis C. The results
could be used for the development of innovative therapeutic schemes and new
drugs which could meet patients’ needs. For IQWiG purposes the weights of PREs
are included in the health economic evaluation.
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PERCEPTIONS ABOUT ’RAPID’ WARFARIN REVERSAL WITH FRESH FROZEN
PLASMA TO REDUCE THE INR: A NOVEL SURVEY METHODOLOGY
Petrozzino J1, Hoesche J2, Jones C2
1Compara Biomedical, Orlando, FL, USA, 2CSL Behring, King of Prussia, PA, USA
OBJECTIVES: To determine health care provider perceptions about timing of ’rapid’
warfarin reversal-related patient care events using novel survey methodology.
METHODS: Forty-eight adult and pediatric trauma centers were contacted to par-
ticipate in a direct-to-provider (DTP) survey. Participants were asked to provide
aggregate information about patients receiving fresh-frozen plasma (FFP) for acute
warfarin reversal. RESULTS: Nineteen to 25 health care professionals from 18 cen-
ters provided information by survey. Average perceptions of time needed to infuse
FFP under this setting (mean 4.6 hrs from time of triage; 95% CI 1.0 – 8.2 hrs) are
consistent with actual, published values. In contrast, average perceptions of time
needed for initial International Normalized Ratio (INR) normalization using FFP
(mean 5.8 hrs; 95% CI 2.8 – 8.8 hrs) underestimate actual, published values by 6 – 26
hrs. Health care providers perceived that relatively little cumulative time lapses
(1.6 hrs, on the average) for completing the first FFP infusion. There is little per-
ceived time lag between ordering and beginning the first FFP infusion (0.3 hrs, on
the average), consistent with actual, published values. There is substantial re-
ported time (an additional 3.0 hrs, on the average) needed to complete subsequent
FFP infusions, amounting to 52% of all perceived time lapsing for initial INR nor-
malization in this setting. CONCLUSIONS: DTP survey methodology appears to be
an efficient method for gathering clinical information for research purposes.
Healthcare providersmay have perceptions that are different frompublished stud-
ies, including inaccurate perceptions of the delay between the time FFP infusions
are completed and time of initial INR normalization. To our knowledge, this is the
first study to show that subsequent-to-first FFP dose infusion times account for the
majority of perceived INRnormalization time. Delays to treatment completionmay
present serious downstream consequences. Such perceptions may influence clin-
ical decision making, and warrant further analysis and investigation.
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OBJECTIVES: To estimate CAP episode incidence and 30-day mortality rates in the
Medicare FFS population 65 years of age.METHODS: Claims data from the Medi-
care 5% sample were used to identify pneumonia diagnoses between July 1, 2007 to
June 30, 2008.We defined pneumonia hospitalizations as either Part A (PA) primary
discharge diagnosis (pdd) of pneumonia, or sepsis or respiratory failure as pdd plus
pneumonia as secondary diagnosis. Outpatient pneumonia was defined as a pneu-
monia diagnosis from PA outpatient or non-hospital sourced Part B, with claim for
chest x-ray within 14 days of pneumonia diagnosis. CAP episodes were defined as
being indexed on the first pneumonia claim date followed through the last pneu-
monia claim date preceded and followed by a 90 day clean period, respectively.
Episodes were defined as outpatient, unless beginning with or containing a CAP
hospitalization, in which case they were considered inpatient CAP episodes. We
further excluded evidence of hospitalization, long-term care and mechanical ven-
tilator use from claims within 14 days of the CAP index date. Incidence and mor-
tality were stratified by inpatient status and age. RESULTS: A total of 56,262 CAP
episodes were identified; 38.4% were inpatient. The average inpatient and outpa-
tient episode length was 32.7 days (SD 46.3) and 12.8 days (SD 27.6), respectively.
Corresponding incidence rates were 1,767/100,000 person-years for inpatient and
2,837/100,000 for outpatient CAP. Overall incidence rises with increasing age, rang-
ing from 2,786/100,000 person-years for those 65-69 to 8,449/100,000 for those 85.
Overall 30-day case-fatality was 5.6%; 8.5% for inpatient and 3.8% for outpatient
CAP. Case-fatality rates also increase with increasing age. CONCLUSIONS: The
overall incidence of CAP in the Medicare FFS population of 4,604/100,000 person-
years is substantial. These results suggest an estimated 1.13 million cases of CAP
and 63,000 CAP-related deaths annually among this population. CAP remains an
important public health burden in the United States.
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DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
AND META-ANALYSIS
Park T, Shamliyan TA
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: This study systematically reviews existing evidence to determine the
efficacy and adverse events of dutasteride, alone or in combination, versus a pla-
cebo or control, used for the treatment of benign prostatic hyperplasia (BPH).
METHODS:Medline and the Cochrane Library were searched for randomized con-
trolled trials that were longer than six months in duration. The study population
was men, aged 50 or older, with moderate and severe symptoms of BPH as deter-
mined by the International Prostate Symptom Score (IPSS) and clinical parameters
includingmaximumurinary flow rate (Qmax) and prostate volume. Ameta-analysis
with a random effects model was conducted to synthesize the findings of multiple
studies. Heterogeneity among the studies was assessed both graphically with for-
est plots and statistically with I2 statistics. RESULTS: Dutasteride was superior to
the placebo in reducing urinary symptoms measured by IPSS [weighted mean dif-
ference (WMD)  2.50, 95% confidence intervals (CIs)  2.91 to 2.09], prostate
volume (WMD12.90, 95% CIs14.27 to11.53) and in increasing Qmax (WMD
1.30, 95% CIs  0.99 to 1.61). However, risk ratios for any adverse events (1.27, 95%
CIs  0.99 to 1.62) and for drug-related adverse events (1.47, 95% CIs  0.77 to 2.79)
were not significantly different between those treated with dutasteride and those
in the control group. When dutasteride was administered with tamsulosin, the
reduction in IPSS scores and the increase in Qmax were greater than if the medica-
tions were administered alone, although prostate volume changed little. For both
BPH-related acute urinary retention (AUR) and BPH-related surgery, no significant
difference in risk ratio was observed between the combination group and the du-
tasteride group. CONCLUSIONS: Dutasteride can be used for those with moderate
to severe BPH symptoms when benefits from efficacy are considered to be greater
than the loss from adverse events.
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OBJECTIVES: The incidence of acute renal failure (ARF) is increasing. A substantial
proportion of these cases are due to drug-induced nephrotoxicity. Data from post-
marketing surveillance programs, like the FDA Adverse Event Reporting System
(AERS), can be useful in assessing the risk of adverse drug events. Our objective is to
describe reports with ARF (cases) and reports without ARF (non-cases) and out-
comes resulting from ARF using the AERS database. METHODS: Data were ex-
tracted from the AERS database from 2004–2009. All reports of cases and non-cases
were described and analyzed in term of suspected drugs, health outcomes, and
other characteristics. Descriptive statistics (frequencies and proportions) and Chi-
square tests were used. RESULTS: The AERS data used in this study represents
2,231,689 reports from 184 countries with 27,190 involving reports of ARF (cases).
There was approximately a two-fold increase in the percentage of reports of ARF
from 2004 to 2009 (n 3,594; 13% to n 6,104; 22%, respectively). Most reports were
submitted by manufacturers (cases  89%, non-cases 93%). The majority of re-
ports were for infants (cases  75%, non-cases  57%). In cases, drugs were the
primary suspect, the secondary suspect and concomitant in 18%, 14% and 66% of
reports, respectively. The five drugs with the highest reported frequencies of ARF
were rofecoxib, valacyclovir, metformin, simvastatin, and digoxin. Unfavorable
outcomesweremore likely to occur in cases than non-cases (death 24% vs. 12%, life
threatening condition 21% vs. 5%, initial/prolonged hospitalization 76% vs. 33%,
disability 6% vs. 4% and required intervention 4% vs. 2%; p-value  0.001, for all
comparisons). CONCLUSIONS: These preliminary findings present an overall pic-
ture of reports with ARF. These findings can be informative for regulatory author-
ities and healthcare professionals. Additional analyses with reporting odd ratios
(ROR) are needed to support these initial findings.
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OBJECTIVES: To examine the relationship between NSAID use and the progression
of CKD for a cohort of elderly patients within the military health system.
METHODS:All patients with at least one serum creatininemeasurement in each of
the time periods July 1–December 31, 2006 and July 1–December 31, 2008 with a
baseline estimated glomerular filtration rate (eGFR) representing CKD stage 2 or 3,
whowere 67 years of age, continuously eligible for TRICARE, and received care at
a military treatment facility were included in a retrospective database analysis.
Logistic regression analyses were used to explore associations between NSAID use
and rapid progression of CKDdefined as a decrease in eGFR of 15mL/min/1.73m2.
Covariates included age, gender, diabetes, hyperlipidemia, hypertension, and
NSAID exposure level. RESULTS: A total of 34,295 patients (median age 73.5, 50.2%
male) met the inclusion/exclusion criteria. A total of 14,576 patients had some
NSAID use, while 19,719 had no NSAID use. Rapid CKD progression occurred for
10.5% of no useNSAID patients (2,063 of 19,720), 11.2% of low tomediumNSAID use
patients (1,465 of 13,125), and 13.4% of high NSAID use patients (195 of 1,450).
Logistic regression results showed that stage 2-3 CKD patients with low tomedium
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